ALK and non-small cell lung carcinoma: Similarly, significantly common co-occurring gene alterations among RET fusion-negative vs positive NSCLC patients include TP53, KRAS, STK11, EGFR, PIK3CA, RB1, NF1, SMARCA4, KEAP1, RBM10, ARID1A, KMT2D, SOX2, MET, BRAF, NSD3, ALK, ROS1, and ERBB2 (P < 0.001; Fig. 3a and Supplementary Table 6).